Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, and commercializing pharmaceutical products for rare diseases. The company offers INCRELEX, treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD); ALKINDI SPRINKLE, as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age, and accurate dosing for newborns and children with AI; GALZIN, as a maintenance treatment for patients with Wilson Disease who have been initially treated with a chelating agent; PKU GOLIKE, medical formula for the dietary management of phenylketonuria (PKU); Carglumic Acid, treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency; Betaine Anhydrous, for the treatment of homocystinuria; Nitisinone for the treatment of tyrosinemia type 1; and Amglidia for the treatment of neonatal diabetes mellitus products. It also develops ET-600 for the treatment of central diabetes insipidus; ET-700 for the treatment of treatment of Wilson disease; ET-800; Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals Inc.

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Eton Pharmaceuticals today and set a price target of $35.00. According to...

H.C. Wainwright Sticks to Its Buy Rating for Eton Pharmaceuticals (ETON)

The latest announcement is out from Eton Pharmaceuticals ( ($ETON) ). On December 4, 2025, Eton Pharmaceuticals, Inc. management will attend the Pi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ETON	$16.99	+2.66%	167.53K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ETON	$16.99	+2.7%	167.53K
3
4
5
6

ETON

ETON

Get Eton Pharmaceuticals Inc. Data in Excel

Get Eton Pharmaceuticals Inc. Data in Excel